Malignant pleural mesothelioma (MPM) · line 1 · Pemetrexed + cisplatin (malignant pleural mesothelioma, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMETREXED-CISPLATIN-MPM |
| ID | IND-MESOTHELIOMA-1L-PEMETREXED-PLATINUM |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-MESOTHELIOMA |
| Sources | SRC-CHECKMATE-743-BAAS-2021 SRC-EMPHACIS-VOGELZANG-2003 |
Notes
Pemetrexed+carboplatin (AUC 5) is an equivalent alternative for cisplatin-ineligible patients — no phase 3 head-to-head but widely accepted (NCCN Category 2A). Pemetrexed maintenance after 6 cycles of doublet: not standard per EMPHACIS; some centers use pemetrexed maintenance for responding patients (off-label). Post-ICI salvage: pemetrexed+platinum is the recommended chemotherapy after progression on nivolumab+ipilimumab (NCCN). Response assessment: modified RECIST (mRECIST for pleural diseases) — measure tumor thickness at 3 perpendicular levels; standard RECIST underestimates MPM progression.
Used By
Algorithms
ALGO-MESOTHELIOMA-1L- ALGO-MESOTHELIOMA-1L